BRPI0519015A2 - composiÇço farmacÊutica, agente profilÁtico ou agente terapÊutico, agentes para melhorar a funÇço das cÉlulas b no pÂncreas, e para a reduÇço da razço da hemoglobina glicosilada, e, usos da 5-[4-(6-metàxi-1-metil-1h-benzimidazol-2-ilmetàxi)benzi l] tiazolidina-2,4-diona ou de um sal farmacologicamente aceitÁvel da mesma e de um inibidor de fbpase, e do 2-amino-5-isobutil-4-[2-[5-(n,n'-bis((s)-1etoxicarbonil)eti l) fosfonamido] furanil} tiazol ou de um sal farmacologicamente aceitÁvel do mesmo - Google Patents
composiÇço farmacÊutica, agente profilÁtico ou agente terapÊutico, agentes para melhorar a funÇço das cÉlulas b no pÂncreas, e para a reduÇço da razço da hemoglobina glicosilada, e, usos da 5-[4-(6-metàxi-1-metil-1h-benzimidazol-2-ilmetàxi)benzi l] tiazolidina-2,4-diona ou de um sal farmacologicamente aceitÁvel da mesma e de um inibidor de fbpase, e do 2-amino-5-isobutil-4-[2-[5-(n,n'-bis((s)-1etoxicarbonil)eti l) fosfonamido] furanil} tiazol ou de um sal farmacologicamente aceitÁvel do mesmoInfo
- Publication number
- BRPI0519015A2 BRPI0519015A2 BRPI0519015-0A BRPI0519015A BRPI0519015A2 BR PI0519015 A2 BRPI0519015 A2 BR PI0519015A2 BR PI0519015 A BRPI0519015 A BR PI0519015A BR PI0519015 A2 BRPI0519015 A2 BR PI0519015A2
- Authority
- BR
- Brazil
- Prior art keywords
- acceptable salt
- benzimidazol
- pharmaceutical composition
- methyl
- ylmethoxy
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title abstract 5
- 239000003795 chemical substances by application Substances 0.000 title abstract 4
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 102000017011 Glycated Hemoglobin A Human genes 0.000 title abstract 2
- 108010014663 Glycated Hemoglobin A Proteins 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title abstract 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 title abstract 2
- 210000000496 pancreas Anatomy 0.000 title abstract 2
- 229940124597 therapeutic agent Drugs 0.000 title abstract 2
- 210000003719 b-lymphocyte Anatomy 0.000 title 1
- 125000002541 furyl group Chemical group 0.000 title 1
- 230000000069 prophylactic effect Effects 0.000 title 1
- XMSXOLDPMGMWTH-UHFFFAOYSA-N rivoglitazone Chemical compound CN1C2=CC(OC)=CC=C2N=C1COC(C=C1)=CC=C1CC1SC(=O)NC1=O XMSXOLDPMGMWTH-UHFFFAOYSA-N 0.000 title 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 2
- ZVIGBJZXNPTZSQ-UHFFFAOYSA-N 2-(furan-2-yl)-1,3-thiazole Chemical compound C1=COC(C=2SC=CN=2)=C1 ZVIGBJZXNPTZSQ-UHFFFAOYSA-N 0.000 abstract 1
- SLRMQYXOBQWXCR-UHFFFAOYSA-N 2154-56-5 Chemical compound [CH2]C1=CC=CC=C1 SLRMQYXOBQWXCR-UHFFFAOYSA-N 0.000 abstract 1
- 101710099475 3'-phosphoadenosine 5'-phosphate phosphatase Proteins 0.000 abstract 1
- 101710196411 Fructose-1,6-bisphosphatase Proteins 0.000 abstract 1
- 101710186733 Fructose-1,6-bisphosphatase, chloroplastic Proteins 0.000 abstract 1
- 101710109119 Fructose-1,6-bisphosphatase, cytosolic Proteins 0.000 abstract 1
- 101710198902 Fructose-1,6-bisphosphate aldolase/phosphatase Proteins 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 229940122355 Insulin sensitizer Drugs 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 230000004064 dysfunction Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 125000005541 phosphonamide group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/664—Amides of phosphorus acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
COMPOSIÇçO FARMACÊUTICA, AGENTE PROFILÁTICO OU AGENTE TERAPÊUTICO, AGENTES PARA MELHORAR A FUNÇçO DAS CÉLULAS B NO PÂNCREAS, E PARA A REDUÇçO DA RAZçO DA HEMOGLOBiNA GLICOSILADA, E, USOS DA 5-[4-(6-METOXI-1-METIL- 1H-BENZIMIDAZOL-2-ILMETàXI)BENZIL]TIAZOLIDINA-2,4-DIO NA OU DE UM SAL FARMACOLOGICAMENTE ACEITÁVEL DA MESMA E DE UM INIBIDOR DE FBPASE, E DO 2-AMINO-5-ISOBUTIL-4-{2-[5-(N,N'- BIS((S)-1 -ETOXICARBONIL)ETIL)FOSFONAMIDO]FURANIL} TIAZOL OU DE UM SAL FARMACOLOGICAMIENTE ACEITÁVEL DO MESMO. Para fornecer um processo de tratamento para diabete melito que tem excelente atividade decrescente em níveis de glicose no sangue e melhorar os efeitos para a disfunção de células <225> no pâncreas de pacientes com diabete melito. Uma composição farmacêutica compreende um inibidor de FBPase e um sensibilizador para insulina, que é a 5-[4-(6-metóxi-l-metil-íH- benzimidazol-2-ilmetóxi)benziltiazolidina-2,4-diona ou um sal farmacologicamente aceitável da mesma.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2004362246 | 2004-12-15 | ||
| PCT/JP2005/022916 WO2006064826A1 (ja) | 2004-12-15 | 2005-12-14 | FBPase阻害剤を含有する医薬組成物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0519015A2 true BRPI0519015A2 (pt) | 2008-12-23 |
Family
ID=36587882
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0519015-0A BRPI0519015A2 (pt) | 2004-12-15 | 2005-12-14 | composiÇço farmacÊutica, agente profilÁtico ou agente terapÊutico, agentes para melhorar a funÇço das cÉlulas b no pÂncreas, e para a reduÇço da razço da hemoglobina glicosilada, e, usos da 5-[4-(6-metàxi-1-metil-1h-benzimidazol-2-ilmetàxi)benzi l] tiazolidina-2,4-diona ou de um sal farmacologicamente aceitÁvel da mesma e de um inibidor de fbpase, e do 2-amino-5-isobutil-4-[2-[5-(n,n'-bis((s)-1etoxicarbonil)eti l) fosfonamido] furanil} tiazol ou de um sal farmacologicamente aceitÁvel do mesmo |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20070287685A1 (pt) |
| EP (1) | EP1825854A1 (pt) |
| KR (1) | KR20070086137A (pt) |
| CN (1) | CN101115483A (pt) |
| BR (1) | BRPI0519015A2 (pt) |
| CA (1) | CA2591416A1 (pt) |
| TW (1) | TW200633702A (pt) |
| WO (1) | WO2006064826A1 (pt) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8722710B2 (en) | 2007-09-26 | 2014-05-13 | Deuterx, Llc | Deuterium-enriched pioglitazone |
| JP6800013B2 (ja) | 2013-03-14 | 2020-12-16 | ポクセル・ソシエテ・アノニムＰｏｘｅｌ ＳＡ | 重水素化２，４−チアゾリジンジオン及び治療方法 |
| US10188639B2 (en) | 2014-01-15 | 2019-01-29 | Deuterx, Llc | Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone |
| US11319313B2 (en) | 2020-06-30 | 2022-05-03 | Poxel Sa | Crystalline forms of deuterium-enriched pioglitazone |
| US11767317B1 (en) | 2020-06-30 | 2023-09-26 | Poxel Sa | Methods of synthesizing enantiopure deuterium-enriched pioglitazone |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ293016B6 (cs) * | 1995-06-01 | 2004-01-14 | Sankyo Company Limited | Benzimidazolové deriváty a farmaceutické prostředky s jejich obsahem |
| WO2000014095A1 (en) * | 1998-09-09 | 2000-03-16 | Metabasis Therapeutics, Inc. | Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase |
| RU2227749C2 (ru) * | 1998-12-24 | 2004-04-27 | Метабэйсис Терапьютикс, Инк. | Комбинация ингибиторов fbpазы и сенсибилизаторов инсулина для лечения диабета |
| US6756360B1 (en) * | 1998-12-24 | 2004-06-29 | Metabasis Therapeutics, Inc. | Combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes |
| TWI284533B (en) * | 1999-05-24 | 2007-08-01 | Sankyo Co | Pharmaceutical composition for treating hyperglycemia, impaired glucose tolerance, diabetes complications and for improving insulin resistant |
| EP1240174A2 (en) * | 1999-12-22 | 2002-09-18 | Metabasis Therapeutics, Inc. | Novel bisamidate phosphonate prodrugs |
| KR20020079988A (ko) * | 2000-03-08 | 2002-10-21 | 메타베이시스 테라퓨틱스, 인크. | 신규한 아릴 프럭토스-1,6-비스포스파타제 억제제 |
| US7563774B2 (en) * | 2000-06-29 | 2009-07-21 | Metabasis Therapeutics, Inc. | Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes |
| US6866866B1 (en) * | 2000-11-03 | 2005-03-15 | Andrx Labs, Llc | Controlled release metformin compositions |
| EP1535630A1 (en) * | 2002-07-23 | 2005-06-01 | Sankyo Company, Limited | Preventive for the onset of diabetes |
-
2005
- 2005-12-14 BR BRPI0519015-0A patent/BRPI0519015A2/pt not_active Application Discontinuation
- 2005-12-14 TW TW094144174A patent/TW200633702A/zh unknown
- 2005-12-14 WO PCT/JP2005/022916 patent/WO2006064826A1/ja not_active Ceased
- 2005-12-14 KR KR1020077013335A patent/KR20070086137A/ko not_active Withdrawn
- 2005-12-14 CA CA002591416A patent/CA2591416A1/en not_active Withdrawn
- 2005-12-14 EP EP05816808A patent/EP1825854A1/en not_active Withdrawn
- 2005-12-14 CN CNA2005800479725A patent/CN101115483A/zh active Pending
-
2007
- 2007-06-14 US US11/818,534 patent/US20070287685A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| TW200633702A (en) | 2006-10-01 |
| WO2006064826A1 (ja) | 2006-06-22 |
| EP1825854A1 (en) | 2007-08-29 |
| KR20070086137A (ko) | 2007-08-27 |
| CA2591416A1 (en) | 2006-06-22 |
| US20070287685A1 (en) | 2007-12-13 |
| CN101115483A (zh) | 2008-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Nauck | Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications | |
| SG149814A1 (en) | Compositions and methods for treating diabetes | |
| DK1572230T3 (da) | Placenta alkalisk phosphatase til at kontrollere diabetes | |
| BR0011891A (pt) | Composto, composição farmacêutica, uso de um composto, métodos para tratamento de uma doença ou condição mediada pelo hpparso , para diminuir triglicerìdios em um paciente, para tratar a diabete do tipo 2, diminuir a resistência à insulina ou abaixar a pressão sanguìnea em um paciente, para diminuir os nìveis de fribogênio em um paciente, para diminuir o ldlc em um paciente e para mudar o tamanho da partìcula do ldl denso pequeno para denso normal em um paciente, e , uso de uma agonista hpparso | |
| PE20110396A1 (es) | Tratamiento de la diabetes en pacientes con control glucemico insuficiente a pesar de la terapia con un farmaco oral o no oral antidiabetico | |
| Brown | Cardiovascular effects of antidiabetic agents: focus on blood pressure effects of incretin-based therapies | |
| NZ623123A (en) | A process for concentration of a polypeptide | |
| BRPI0414455A (pt) | métodos para usar células regenerativas no tratamento de doença vascular periférica e distúrbios afins | |
| MXPA05006994A (es) | Composiciones y metodos para la prevencion y el control de hipoglucemia inducida por insulina. | |
| Bocci et al. | An integrated medical treatment for type-2 diabetes | |
| DE60215866D1 (de) | Medikament, enthaltend cyanidin-3-glykosid als wirkstoff gegen fettsucht und diabetes | |
| EP1543158A4 (en) | REGULATED APTAMER THERAPEUTICS | |
| EP1742643A4 (en) | MODULATION OF GLUCOSE-6-PHOSPHATASE TRANSLOKASE EXPRESSION | |
| EA201070557A1 (ru) | Способы и композиции для замедления набора веса, связанного с применением атипичных антипсихотических препаратов | |
| Brown et al. | Influence of ischemia-reperfusion injury on cardiac metabolism | |
| Pfister et al. | Inhibition of SGLT2: a novel strategy for treatment of type 2 diabetes mellitus | |
| Ho et al. | Refractive hypotension in a patient with disulfiram-ethanol reaction | |
| EA200600402A1 (ru) | Клеточные стенки дрожжей для лечения или профилактики гипергликемии или для стабилизации уровня сахара в крови | |
| BR112013009043A2 (pt) | composto, uso de um composto, e, método para tratar uma doença | |
| BR0213429A (pt) | Métodos para regenerar a função do pâncreas em um indivìduo, para tratar o diabete em um paciente humano e para produzir célula pancreática funcional de animal, célula pancreática funcional de animal, uso da mesma, e, método para roduzir célula pancreática de animal em diferentes estágios de desenvolvimento | |
| PE108199A1 (es) | Composicion farmaceutica de tiazolidindiona y sulfonilurea | |
| BRPI0418963A (pt) | composição para redução de gordura localizada, uso de compostos tensoativos farmceuticamente aceitáveis e métodos para redução de gordura localizada | |
| BR0312463A (pt) | Prática terapêutica ou profilática contra o diabetes mellitus e a obesidade; métodos de redução do nìvel de glicose no sangue; supressor de apetite; método de prevenção ou tratamento contra o diabete mellitus e a obesidade; e método de supressão de apetite | |
| DK1697401T3 (da) | Tetrapeptid, som regulerer blodglucoseniveauet ved diabetes mellitus | |
| Kwong et al. | Higher incidences of diabetes mellitus during exposure to antipsychotics—findings from a retrospective cohort study in the US |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired |